{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:41:20Z","timestamp":1790523680988,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T00:00:00Z","timestamp":1595116800000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.revmed.2018.12.002","type":"journal-article","created":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T19:10:48Z","timestamp":1548529848000},"page":"545-552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["CAR-T cells\u00a0: lymphocytes exprimant un r\u00e9cepteur chim\u00e9rique \u00e0 l\u2019antig\u00e8ne"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3755-4889","authenticated-orcid":false,"given":"C.","family":"Chabannon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"F\u00fcrst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Saillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Vey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mokart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fougereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lemarie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mfarrej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Calmels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.revmed.2018.12.002_bib0300","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.drudis.2018.01.024","article-title":"From clinical proof-of-concept to commercialization of CAR T cells","volume":"23","author":"Calmels","year":"2018","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.revmed.2018.12.002_bib0305","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrclinonc.2015.187","article-title":"Novel immunotherapies in lymphoid malignancies","volume":"13","author":"Batlevi","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"5235","key":"10.1016\/j.revmed.2018.12.002_bib0310","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4\u00a0years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.revmed.2018.12.002_bib0315","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.revmed.2018.12.002_bib0320","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1056\/NEJMe1714680","article-title":"A milestone for CAR T Cells","volume":"377","author":"Tran","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.revmed.2018.12.002_bib0325","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/trf.14003","article-title":"Autologous lymphapheresis for the production of chimeric antigen receptor T cells","volume":"57","author":"Allen","year":"2017","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.revmed.2018.12.002_bib0330","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/trf.14110","article-title":"CAR-T cell manufacturing: time to put it in gear","volume":"57","author":"Bersenev","year":"2017","journal-title":"Transfusion"},{"issue":"8","key":"10.1016\/j.revmed.2018.12.002_bib0335","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jcyt.2016.05.009","article-title":"Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy","volume":"18","author":"Mock","year":"2016","journal-title":"Cytotherapy"},{"issue":"S1","key":"10.1016\/j.revmed.2018.12.002_bib0340","first-page":"157","article-title":"Production of ARI-0001\u00a0cells (A3B1:CD8:4-1BB:CD3z cells) in patients with CD19+ relapsed\/refractory B-cell malignancies using the CliniMACS Prodigy System","volume":"2","author":"Caballero-Ba\u00f1os","year":"2018","journal-title":"HemaSphere"},{"issue":"10","key":"10.1016\/j.revmed.2018.12.002_bib0345","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Cells that express an anti-CD19\u00a0chimeric antigen receptor induce remissions of b-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.revmed.2018.12.002_bib0350","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/mt.2016.106","article-title":"Translational implications for off-the-shelf immune cells expressing chimeric antigen receptors","volume":"24","author":"Torikai","year":"2016","journal-title":"Mol Ther"},{"issue":"10","key":"10.1016\/j.revmed.2018.12.002_bib0355","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood-2015-08-664250","article-title":"Murine allogeneic CD19\u00a0CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD","volume":"127","author":"Jacoby","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.revmed.2018.12.002_bib0360","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nm.4258","article-title":"Donor CD19\u00a0CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity","volume":"23","author":"Ghosh","year":"2017","journal-title":"Nat Med"},{"issue":"374","key":"10.1016\/j.revmed.2018.12.002_bib0365","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.revmed.2018.12.002_bib0370","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.revmed.2018.12.002_bib0375","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19\u00a0CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.revmed.2018.12.002_bib0380","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19\u00a0CAR-T cells of defined CD4+:CD8+ composition in adult B-cell all patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.revmed.2018.12.002_bib0385","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51\u00a0refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.revmed.2018.12.002_bib0390","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19\u00a0CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"9967","key":"10.1016\/j.revmed.2018.12.002_bib0395","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19\u00a0chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1\u00a0dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.revmed.2018.12.002_bib0400","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.revmed.2018.12.002_bib0405","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T Cells in refractory B-Cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"355","key":"10.1016\/j.revmed.2018.12.002_bib0410","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"303","key":"10.1016\/j.revmed.2018.12.002_bib0415","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"26","key":"10.1016\/j.revmed.2018.12.002_bib0420","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.revmed.2018.12.002_bib0425","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19\u00a0chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.revmed.2018.12.002_bib0430","first-page":"194","article-title":"Chimeric Antigen Receptor T Cells in myeloma","volume":"374","author":"Garfall","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.revmed.2018.12.002_bib0435","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19\u00a0enables resistance to CART-19\u00a0immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"20","key":"10.1016\/j.revmed.2018.12.002_bib0440","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19\u00a0CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.revmed.2018.12.002_bib0445","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.revmed.2018.12.002_bib0450","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.revmed.2018.12.002_bib0455","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.revmed.2018.12.002_bib0460","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.revmed.2018.12.002_bib0465","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.revmed.2018.12.002_bib0470","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","article-title":"Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1","volume":"25","author":"Tashiro","year":"2017","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.revmed.2018.12.002_bib0475","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.revmed.2018.12.002_bib0480","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.revmed.2018.12.002_bib0485","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123\u00a0antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.revmed.2018.12.002_bib0490","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.revmed.2018.12.002_bib0495","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.revmed.2018.12.002_bib0500","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"issue":"1","key":"10.1016\/j.revmed.2018.12.002_bib0505","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.revmed.2018.12.002_bib0510","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.bbmt.2018.04.010","article-title":"Peripheral blood grafts for T cell-replete haploidentical transplantation increase the incidence and severity of cytokine release syndrome","volume":"24","author":"Raj","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"10.1016\/j.revmed.2018.12.002_bib0515","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19\u00a0chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.revmed.2018.12.002_bib0520","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.revmed.2018.12.002_bib0525","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2018.12.002_bib0530","unstructured":"EMA. Patient Registries Workshop, 28\u00a0October 2016: Observations and recommendations arising from the workshop 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2017\/02\/WC500221618.pdf 2017 [30 d\u00e9cembre 2018]"},{"issue":"19","key":"10.1016\/j.revmed.2018.12.002_bib0535","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/jama.2017.15218","article-title":"FDA Approval of Tisagenlecleucel. Promise and Complexities of a $475 000\u00a0Cancer Drug","volume":"318","author":"Bach","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.revmed.2018.12.002_bib0540","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrclinonc.2017.156","article-title":"Immunotherapy: Tisagenlecleucel \u2013 the first approved CAR-T-cell therapy: implications for payers and policy makers","volume":"15","author":"Prasad","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.revmed.2018.12.002_bib0545","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/bmt.2017.241","article-title":"CAR-T cells: the narrow path between hope and bankruptcy?","volume":"52","author":"Chabannon","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"33","key":"10.1016\/j.revmed.2018.12.002_bib0550","article-title":"Hematopoietic stem cell transplantation in its 60s: a platform for cellular therapies","volume":"9","author":"Chabannon","year":"2017","journal-title":"Sci Transl Med"},{"issue":"14","key":"10.1016\/j.revmed.2018.12.002_bib0555","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMp1711886","article-title":"Tragedy, Perseverance, and chance \u2013 The story of CAR-T therapy","volume":"377","author":"Rosenbaum","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.revmed.2018.12.002_bib0560","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrd.2017.84","article-title":"CAR T therapies drive into new terrain","volume":"16","author":"Kingwell","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"6295","key":"10.1016\/j.revmed.2018.12.002_bib0565","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.revmed.2018.12.002_bib0570","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.revmed.2018.12.002_bib0575","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/annonc\/mdx755","article-title":"Comprehensive analysis of the clinical immuno-oncology landscape","volume":"29","author":"Tang","year":"2018","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.revmed.2018.12.002_bib0580","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.revmed.2018.12.002_bib0585","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat Nanotechnol"},{"issue":"12S","key":"10.1016\/j.revmed.2018.12.002_bib0295","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.bulcan.2017.10.017","article-title":"Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"104","author":"Yakoub-Agha","year":"2017","journal-title":"Bull Cancer"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866318311895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866318311895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:41:38Z","timestamp":1759336898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866318311895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0248866318311895"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2018.12.002","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cells\u00a0: lymphocytes exprimant un r\u00e9cepteur chim\u00e9rique \u00e0 l\u2019antig\u00e8ne","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2018.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}